Ciputra Adijaya Hartana1, Xu G Yu1,2. 1. Ragon Institute of MGH, MIT and Harvard, Cambridge. 2. Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: HIV-1 elite controllers encompass small populations of people infected with HIV-1 who can spontaneously control plasma viral loads below the limit of detection, in the absence of antiretroviral treatment. Antiviral immune responses are likely to contribute to such an impressive HIV-1 disease outcome. In this review, we discuss recent novel findings regarding antiviral innate and adaptive immune responses in elite controllers. RECENT FINDINGS: Elite controllers maintain a pool of infected cells in which intact HIV-1 proviruses are more frequently integrated into noncoding regions of the host genome, likely conferring a state of deep latency. This atypical viral reservoir configuration is best explained by potent antiviral immune responses that can successfully eliminate virally infected cells in which proviruses are integrated into permissive chromatin. However, identifying the specific type and nature of this immune selection pressure represents a formidable challenge. Recent studies continue to support the role of HIV-1-specific CD8+ T cells as the main driver of elite immune control of HIV-1, however, increasing evidence suggests that their role is complemented by a fine-tuned interplay with innate immune cell subsets. Therefore, the combination of different immune effector mechanisms may shape antiviral immunity in elite controllers. SUMMARY: Understanding the complex immune mechanisms responsible for natural, drug-free HIV-1 control represents a premier avenue to find and develop interventions for a cure of HIV-1 infection. Future single-cell assays designed to uncover the full genetic, epigenetic, transcriptional and functional complexity of antiviral immune responses in elite controllers may allow us to define correlates of antiviral immune protection in greater detail.
PURPOSE OF REVIEW: HIV-1 elite controllers encompass small populations of people infected with HIV-1 who can spontaneously control plasma viral loads below the limit of detection, in the absence of antiretroviral treatment. Antiviral immune responses are likely to contribute to such an impressive HIV-1 disease outcome. In this review, we discuss recent novel findings regarding antiviral innate and adaptive immune responses in elite controllers. RECENT FINDINGS: Elite controllers maintain a pool of infected cells in which intact HIV-1 proviruses are more frequently integrated into noncoding regions of the host genome, likely conferring a state of deep latency. This atypical viral reservoir configuration is best explained by potent antiviral immune responses that can successfully eliminate virally infected cells in which proviruses are integrated into permissive chromatin. However, identifying the specific type and nature of this immune selection pressure represents a formidable challenge. Recent studies continue to support the role of HIV-1-specific CD8+ T cells as the main driver of elite immune control of HIV-1, however, increasing evidence suggests that their role is complemented by a fine-tuned interplay with innate immune cell subsets. Therefore, the combination of different immune effector mechanisms may shape antiviral immunity in elite controllers. SUMMARY: Understanding the complex immune mechanisms responsible for natural, drug-free HIV-1 control represents a premier avenue to find and develop interventions for a cure of HIV-1 infection. Future single-cell assays designed to uncover the full genetic, epigenetic, transcriptional and functional complexity of antiviral immune responses in elite controllers may allow us to define correlates of antiviral immune protection in greater detail.
Authors: Marcus Buggert; Son Nguyen; Gonzalo Salgado-Montes de Oca; Bertram Bengsch; Samuel Darko; Amy Ransier; Emily R Roberts; Daniel Del Alcazar; Irene Bukh Brody; Laura A Vella; Lalit Beura; Sathi Wijeyesinghe; Ramin S Herati; Perla M Del Rio Estrada; Yuria Ablanedo-Terrazas; Leticia Kuri-Cervantes; Alberto Sada Japp; Sasikanth Manne; Shant Vartanian; Austin Huffman; Johan K Sandberg; Emma Gostick; Gregory Nadolski; Guido Silvestri; David H Canaday; David A Price; Constantinos Petrovas; Laura F Su; Golnaz Vahedi; Yoav Dori; Ian Frank; Maxim G Itkin; E John Wherry; Steven G Deeks; Ali Naji; Gustavo Reyes-Terán; David Masopust; Daniel C Douek; Michael R Betts Journal: Sci Immunol Date: 2018-06-01
Authors: Rebecca T Veenhuis; Abena K Kwaa; Caroline C Garliss; Rachel Latanich; Maria Salgado; Christopher W Pohlmeyer; Christopher L Nobles; John Gregg; Eileen P Scully; Justin R Bailey; Frederic D Bushman; Joel N Blankson Journal: JCI Insight Date: 2018-09-20
Authors: Victoria Stary; Ram Vinay Pandey; Johanna Strobl; Lisa Kleissl; Patrick Starlinger; David Pereyra; Wolfgang Weninger; Gottfried F Fischer; Christoph Bock; Matthias Farlik; Georg Stary Journal: Sci Immunol Date: 2020-10-16
Authors: Christopher W Pohlmeyer; Veronica D Gonzalez; Alivelu Irrinki; Ricardo N Ramirez; Li Li; Andrew Mulato; Jeffrey P Murry; Aaron Arvey; Rebecca Hoh; Steven G Deeks; George Kukolj; Tomas Cihlar; Stefan Pflanz; Garry P Nolan; Gundula Min-Oo Journal: J Virol Date: 2019-03-21 Impact factor: 5.103
Authors: Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup Journal: Blood Date: 2006-02-07 Impact factor: 22.113
Authors: Antigoni Morou; Elsa Brunet-Ratnasingham; Mathieu Dubé; Roxanne Charlebois; Eloi Mercier; Sam Darko; Nathalie Brassard; Krystelle Nganou-Makamdop; Sahaana Arumugam; Gabrielle Gendron-Lepage; Lifei Yang; Julia Niessl; Amy E Baxter; James M Billingsley; Premeela A Rajakumar; François Lefebvre; R Paul Johnson; Cécile Tremblay; Jean-Pierre Routy; Richard T Wyatt; Andrés Finzi; Daniel C Douek; Daniel E Kaufmann Journal: Nat Immunol Date: 2019-07-15 Impact factor: 25.606
Authors: Gisele Umviligihozo; Jaclyn K Mann; Steven W Jin; Francis M Mwimanzi; Hua-Shiuan A Hsieh; Hanwei Sudderuddin; Guinevere Q Lee; Helen Byakwaga; Conrad Muzoora; Peter W Hunt; Jeff N Martin; Jessica E Haberer; Etienne Karita; Susan Allen; Eric Hunter; Zabrina L Brumme; Mark A Brockman Journal: Front Virol Date: 2022-06-16
Authors: Nadia Madrid-Elena; Sergio Serrano-Villar; Carolina Gutiérrez; Beatriz Sastre; Matías Morín; Laura Luna; Laura Martín; Javier Santoyo-López; María Rosa López-Huertas; Elena Moreno; María Laura García-Bermejo; Miguel Ángel Moreno-Pelayo; Santiago Moreno Journal: Front Immunol Date: 2022-09-26 Impact factor: 8.786